Last updated: February 22, 2026
What is NDC 64380-0203?
NDC 64380-0203 represents Vasopressin (Vasostrict), a synthetic form of the naturally occurring hormone vasopressin. It is used as a vasoconstrictor to treat hypotensive states such as vasodilatory shock, cardiac arrest, and bleeding due to esophageal varices. The drug is supplied in single-dose vials for intravenous administration.
Market Overview
The vasopressin market has experienced limited growth compared to newer vasopressors, driven primarily by its established role in critical care and limited competition. As of 2022, the global vasopressin market was valued at approximately $300 million. North America accounts for roughly 55% of the market, fueled by high ICU utilization and stable prescribing patterns.
Key Competitors and Alternatives
- Vasopressin (Vasostrict): Manufactured by Fresenius Kabi.
- Norepinephrine: Dominates vasopressor class with broader indications.
- Epinephrine: Used in cardiac arrest.
- Vasopressin analogs: Such as terlipressin, primarily approved in certain regions (e.g., Europe).
Regulatory Landscape
Vasopressin is approved by the FDA for vasodilatory shock and certain bleeding emergencies. The drug remains off-patent, allowing multiple generic manufacturing entities to participate in the market, exerting downward pressure on prices.
Market Drivers
- Increase in critical care admissions.
- Adoption of vasopressors in septic shock.
- Guidelines recommending vasopressin as adjunct therapy for vasodilatory shock.
- Stable hospital formulary usage, especially in intensive care settings.
Market Constraints
- Competition from cheaper generic alternatives.
- Limited volume growth potential due to specific indication scope.
- Strict hospital formulary access controls.
- Niche clinical positioning relative to newer vasopressors.
Price Projections and Cost Structure
Historical Pricing
In the US, bulk vial prices (per 1 mL) for vasopressin have ranged from $0.70 to $1.20 in recent years, with average single-dose vial tariffs around $8 to $12.
| Year |
Average Price per Vial (USD) |
Market Volume (annual units) |
Estimated Revenue (USD) |
| 2020 |
$10 |
30,000 |
$300 million |
| 2022 |
$9 |
32,000 |
$288 million |
Price Projections (Next 3-5 Years)
Considering generic competition continues to intensify, prices are likely to decline by 2-4% annually.
| Year |
Projected Average Price per Vial |
Estimated Market Volume |
Anticipated Revenue |
| 2023 |
$8.75 |
33,000 |
$288 million |
| 2024 |
$8.50 |
34,000 |
$289 million |
| 2025 |
$8.25 |
35,000 |
$289 million |
Note: Volume increases are driven by clinical adoption stability and ICU patient volume growth.
Price Drivers
- Entry of biosimilars or new formulations.
- Hospital procurement policies favoring cost reduction.
- Changes in clinical guidelines that could alter prescribing behaviors.
Future Market Considerations
The market for vasopressin remains largely stable but mature. No significant pipeline entrants or reformulations are expected to drastically alter dynamics within the next five years. Pricing will be dictated primarily by economic factors influencing hospital procurement practices and competition.
Key Takeaways
- The US vasopressin market for NDC 64380-0203 (Vasostrict) is approximately $288-$289 million currently.
- Prices will likely decrease gradually due to generic competition.
- Volume growth hinges on continued critical care demand, with capacity for modest annual increases.
- Market stability is influenced by existing clinical protocols and high ICU utilization.
FAQs
1. How does vasopressin compare to other vasopressors in the market?
Vasopressin occupies a niche as adjunct therapy in vasodilatory shock; it is generally used after first-line agents like norepinephrine. Its cost and specific indications limit broader use.
2. What is the outlook for pricing with upcoming biosimilar entries?
Biosimilar entry may further reduce prices by 10-20%, especially if multiple manufacturers compete within the same indication.
3. Are there regional differences affecting the market?
Yes. Europe has approved vasopressin for additional indications, such as its use in cases of esophageal variceal bleeding, which can influence regional sales volumes.
4. How sensitive is the market to changes in ICU admission rates?
Critical care admissions directly impact vasopressin demand. A 10% increase in ICU admissions could proportionally increase market volume.
5. What is the potential impact of new vasopressor agents?
Emerging agents with better safety profiles, easier administration, or broader indications could displace vasopressin, exerting downward pressure on market size and prices.
References
[1] MarketWatch. (2022). Vasopressin market size and forecasts. https://marketwatch.com
[2] IQVIA. (2022). US hospital procurement data. https://iqvia.com
[3] FDA. (2022). Vasopressin approval overview. https://fda.gov
[4] GlobalData. (2022). Critical care therapeutics market report. https://globaldata.com
[5] Statista. (2022). Critical care drugs revenue estimates. https://statista.com
